Francis I Proctor Foundation, University of California, San Francisco, California.
Department of Ophthalmology, University of California, San Francisco, California.
Am J Trop Med Hyg. 2022 Dec 12;108(1):206-211. doi: 10.4269/ajtmh.22-0381. Print 2023 Jan 11.
Antibiotics are routinely used as part of the management of severe acute malnutrition and are known to reduce gut microbial diversity in non-malnourished children. We evaluated gut microbiomes in children participating in a randomized controlled trial (RCT) of azithromycin versus amoxicillin for severe acute malnutrition. Three hundred one children aged 6 to 59 months with uncomplicated severe acute malnutrition (mid-upper arm circumference < 11.5 cm and/or weight-for-height Z-score < -3 without clinical complications) were enrolled in a 1:1 RCT of single-dose azithromycin versus a 7-day course of amoxicillin (standard of care). Of these, 109 children were randomly selected for microbiome evaluation at baseline and 8 weeks. Rectal swabs were processed with metagenomic DNA sequencing. We compared alpha diversity (inverse Simpson's index) at 8 weeks and evaluated relative abundance of microbial taxa using DESeq2. Of 109 children enrolled in the microbiome study, 95 were followed at 8 weeks. We found no evidence of a difference in alpha diversity between the azithromycin and amoxicillin groups at 8 weeks controlling for baseline diversity (mean difference -0.6, 95% CI -1.8 to 0.6, P = 0.30). Gut microbiomes did not diversify during the study. Differentially abundant genera at the P < 0.01 level included Salmonella spp. and Shigella spp., both of which were overabundant in the azithromycin compared with amoxicillin groups. We found no evidence to support an overall difference in gut microbiome diversity between azithromycin and amoxicillin among children with uncomplicated severe acute malnutrition, but potentially pathogenic bacteria that can cause invasive diarrhea were more common in the azithromycin group. Trial Registration: ClinicalTrials.gov NCT03568643.
抗生素通常被用作严重急性营养不良管理的一部分,已知会降低非营养不良儿童的肠道微生物多样性。我们评估了参与阿奇霉素与阿莫西林治疗严重急性营养不良的随机对照试验(RCT)的儿童的肠道微生物组。301 名年龄在 6 至 59 个月的患有非复杂性严重急性营养不良(中上臂周长 < 11.5 厘米和/或体重与身高 Z 评分 < -3 无临床并发症)的儿童参与了阿奇霉素与阿莫西林单剂量与 7 天疗程的 1:1 RCT(标准护理)。其中,109 名儿童在基线和 8 周时随机选择进行微生物组评估。直肠拭子用宏基因组 DNA 测序进行处理。我们比较了 8 周时的 alpha 多样性(倒数 Simpson 指数),并使用 DESeq2 评估了微生物分类群的相对丰度。在参与微生物组研究的 109 名儿童中,有 95 名在 8 周时进行了随访。我们发现,在控制基线多样性的情况下,阿奇霉素组和阿莫西林组在 8 周时的 alpha 多样性没有差异(平均差异 -0.6,95%CI-1.8 至 0.6,P = 0.30)。肠道微生物组在研究期间没有多样化。在 P < 0.01 水平上差异丰富的属包括沙门氏菌属和志贺氏菌属,这两种菌在阿奇霉素组中比阿莫西林组更为丰富。我们没有发现证据支持阿奇霉素和阿莫西林在无并发症严重急性营养不良儿童中的肠道微生物组多样性存在总体差异,但可能引起侵袭性腹泻的潜在病原菌在阿奇霉素组中更为常见。试验注册:ClinicalTrials.gov NCT03568643。